Genomics can reveal the true nature of a patient's tumor

While clinical information such as stage and pathology are important in evaluating cancer, the unique genomic blueprint of a patient's tumor is essential in optimizing treatment.


Also available on our YouTube channel
Decipher Prostate Case Review: Impact of Genomics in Decision Making for Intermediate Risk Disease
Webinar #4

Featuring Dr. Ashley Ross of Northwestern University and Dr. Phuoc Tran of Johns Hopkins University

A Genomic Guide to Inform Multidisciplinary Management of Post-RP Radiation Therapy
Webinar #3

Featuring Dr. Edouard Trabulsi, MD and Dr. Robert Den, MD from Thomas Jefferson University

Intermediate Risk Prostate Cancer
Felix Feng, MD

Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses the intermediate risk prostate cancer stratification challenge and the utility of genomics in this setting

Molecular Subtyping in Prostate Cancer
Felix Feng, MD

Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses genomic subtyping in prostate cancer and how it is being investigated in prospective trials

Applying a Clinical Genomic Nomogram for ADT Decisions in Intermediate Risk Prostate Cancer
Webinar #2

Featuring Jeff Michalski, MD, MBA, FASTRO

Decipher Prostate: A Different Approach to Prostate Cancer … We’re Here to Help

Decipher Biosciences has developed a new tool to help with prostate cancer management. A diagnostic test that provides meaningful and independent data to assess the underlying biology and risk of a man's cancer. A test that, when used in conjunction with clinical information, can provide clarity and confidence in determining the best treatment plan.

Using Decipher Testing to Inform ADT Decisions in Intermediate Risk Prostate Cancer
Webinar #1

Overview of the ADT dilemma, current clinical data, and how Decipher testing can help improve decision-making

Decipher in CHAARTED
Dr. Anis Hamid, MBBS

Gene expression profiling of metastatic prostate cancer in the CHAARTED trial reveals predictors of chemotherapy benefit with Dr. Anid Hamid, MBBS, Oncology research fellow at Dana-Farber Cancer Institute

Metastatic Hormone Sensitive Prostate Cancer
Dr. Anis Hamid, MBBS

Dr. Anid Hamid, MBBS, Oncology research fellow at Dana-Farber Cancer Institute share his thoughts on the role of biomarkers for men with metastatic hormone sensitive prostate cancer

The Role of Genomics in Newly Diagnosed Prostate Cancer
Ashley Ross, MD, PhD

Ashley Ross, MD, PhD, Urologist at Texas Urology Specialists share his thoughts on the utility of Decipher in newly diagnosed prostate cancer

Men with High Risk Features Post-RP
Ashley Ross, MD, PhD

Ashley Ross, MD, Urologist at Texas Urology Specialists share his thoughts on RAVES and RADICALS and the utility of Decipher in the management of men with high risk features post-RP

Decipher Can Help Prioritize Patient Follow Up
Robert Den, MD

Robert Den, MD, Radiation Oncologist and Associate Professor at Thomas Jefferson University, on the utility of Decipher Prostate Cancer Classifier in prioritizing patient follow up for men with localized prostate cancer.


Decipher SM Icons

Please enter your name & email address below to download your PDF:

  • This field is for validation purposes and should be left unchanged.